Rishabh Jain, Medical Oncologist at AIIMS, shared a post on X:
“TNBC is no longer a chemo disease.
This 1 algorithm shows the shift: ADCs + biomarkers are now driving frontline decisions.
Metastatic TNBC – how to think today
PD-L1 ≥10
- Pembro + chemo
- OR Pembro + SG
PD-L1 <10
- SG or Dato-DXd now competing with chemo
BRCA-mut
- PARP inhibitors
HER2-low
- T-DXd option
Later lines
- ADC sequencing
- Biomarker-directed therapy
Paradigm shift
- Before: one-size chemo
- Now: IO + ADCs + PARPi + precision oncology
What matters next: Not just ‘which drug’ but ‘what sequence’. Topo-1 ADCs – real cross-resistance concern.
Takeaway
- Advanced TNBC has entered the ADC era
- Smart sequencing will define outcomes.”
Title: Advanced Triple-Negative Breast Cancer: Emerging Therapies and a Changing Treatment Landscape
Authors: Maeve A. Hennessy, Elizabeth Terman, Damé Idossa, Alexis LeVee, Roberto A. Leon-Ferre, Heather McArthur, Rita Nanda
Read the Full Article.
Datopotamab Deruxtecan Improves PFS and OS in First-Line Advanced TNBC in TROPION-Breast02
